Wedbush: Reiterates Aerovate Therapeutics (AVTE.US) rating, adjusted from better than market to better than market rating, with a target price of $41.00.
Wedbush：重申Aerovate Therapeutics(AVTE.US)评级，由优于大市调整至优于大市评级, 目标价41.00美元。
Wedbush: Reiterates Aerovate Therapeutics (AVTE.US) rating, adjusted from better than market to better than market rating, with a target price of $41.00.
The translation is provided by third-party software.
The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.